BetterLife Pharma Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BetterLife Pharma Inc. BetterLife Pharma Inc. (BETRF) is an emerging biotechnology company focused on developing and commercializing patient-friendly, non-hallucinogenic compounds to treat neuro-psychiatric and neurological disorders with high unmet medical needs. The company advances its lead candidate BETR-001 (2-Bromo-LSD or E559), a second-generation lysergic acid diethylamide derivative delivered via oral capsule, which mimics LSD's projected therapeutic effects without hallucinations or regulatory restrictions associated with Schedule 1 psychedelics; BETR-001 targets major depressive disorder, treatment-resistant depression, anxiety disorders, post-traumatic stress disorder, neuropathic pain, cluster headaches, traumatic brain injury, and migraines, supported by issued synthesis patents and pending composition and method-of-use patents extending to approximately 2042. BETR-002 (Dihydrohonokiol-B or DHH-B), also an oral capsule formulation derived from hydrohonokiol in magnolia bark, addresses anxiety-related disorders including benzodiazepine dependency and neurodegenerative conditions, backed by pending method-of-use and formulations patents; additionally, through its wholly owned subsidiary MedMelior, BetterLife owns a preclinical drug candidate for viral infections such as COVID-19 and pursues strategic alternatives for its development. Incorporated in 2002 and headquartered at 1275 West 6th Avenue, Vancouver, British Columbia, Canada, the company operates primarily in Canada with a global development focus on psychiatric and neurological patient populations underserved by current therapies. Recent developments include the November 2025 appointment of Daniel Carcillo, a traumatic brain injury advocate, as Corporate Advisor to accelerate BETR-001 advancement for TBI, cluster headaches, and migraines; earlier appointments of Doug Drysdale as Corporate Advisor and USPTO filing of an Issue Notification for BETR-001 patents; and ongoing preclinical and IND-enabling studies for both lead compounds without reported major acquisitions, funding rounds, or reorganizations in the past 1-2 years.
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen
BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor
Head-To-Head Analysis: Vivos Therapeutics (NASDAQ:VVOS) vs. BetterLife Pharma (OTCMKTS:BETRF)
USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
BetterLife Announces Debt Settlements
BetterLife Pharma Appoints Corporate Advisor
BetterLife Pharma Appoints New Director
BetterLife Announces Debt Conversions
BetterLife Announces Favorable Outcome in New York Legal Claims
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
Ahmad Doroudian Announces Filing of Early Warning Report Related to Ownership of Common Shares of Betterlife Pharma Inc.
Amendment of Disclosures in Past Management Information Circulars
BetterLife Announces Closing of a Private Placement